Anaptysbio (ANAB) Revenue (2016 - 2026)

Anaptysbio has reported Revenue for 11 years, with the latest figure at $25.6 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 7.98% year-over-year to $25.6 million; the trailing twelve-month figure through Mar 2026 stood at $172.8 million (up 119.47% YoY), and the FY2025 full-year result was $234.6 million, up 157.01% from the prior year.
• Revenue for Q1 2026 stood at $25.6 million, down from $75.0 million in the prior quarter.
• The five-year high for Revenue was $75.0 million in Q4 2025, with the low at $970000.0 in Q1 2022.
• Historically, Revenue has averaged $16.7 million across 5 years, with a median of $9.0 million in 2023.
• Annual changes were most pronounced in 2022 — Revenue sank 93.92% — and 2024, when it surged 422.49%.
• Anaptysbio's Revenue stood at $5.0 million in 2022, then soared by 80.1% to $9.0 million in 2023, then jumped by 177.62% to $25.0 million in 2024, then surged by 200.0% to $75.0 million in 2025, then sank by 65.93% to $25.6 million in 2026.
• The last three Revenue figures came in at $25.6 million (Q1 2026), $75.0 million (Q4 2025), and $50.0 million (Q3 2025), per Business Quant data.